Sutro Biopharma Announces Initiation of Randomized Portion (Part 2) of REFRαME-O1 Trial
April 30, 2024 08:00 ET
|
Sutro Biopharma, Inc.
– Part 2 of REFRαME-O1, the registration-directed study of luvelta for patients with platinum-resistant ovarian cancer (PROC), is open for enrollment – – Planned 50 patients in Dose-Optimization...
Sutro Biopharma Announces Pricing of $75 Million Underwritten Offering
April 02, 2024 06:18 ET
|
Sutro Biopharma, Inc.
SOUTH SAN FRANCISCO, Calif., April 02, 2024 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a clinical-stage oncology company pioneering site-specific and...
Sutro Biopharma Reports Full Year 2023 Financial Results, Business Highlights and Select Anticipated Milestones
March 25, 2024 16:30 ET
|
Sutro Biopharma, Inc.
- Sutro highlighted luveltamab tazevibulin (luvelta) in a January 2024 investor webcast, describing the broad opportunity to address unmet needs in multiple FolRα-expressing cancers - - Compelling...
Sutro Biopharma to Participate in Upcoming Investor Conferences
February 06, 2024 16:05 ET
|
Sutro Biopharma, Inc.
SOUTH SAN FRANCISCO, Calif., Feb. 06, 2024 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a clinical-stage oncology company pioneering site-specific and...
Sutro Biopharma Highlights Potential Multi-Cancer Opportunity for Luvelta, a FolRα-targeting ADC
January 04, 2024 16:05 ET
|
Sutro Biopharma, Inc.
Ovarian cancer data supports registration-enabling trial of luvelta for women with platinum-resistant ovarian cancer Potential benefit to 8 out of 10 platinum-resistant ovarian cancer patients,...
Sutro Biopharma to Host Investor Webcast Highlighting Potential Multi-Cancer Opportunity for Luvelta, a FolRα-targeted ADC, on January 4, 2024
December 14, 2023 16:05 ET
|
Sutro Biopharma, Inc.
SOUTH SAN FRANCISCO, Calif., Dec. 14, 2023 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a clinical-stage oncology company pioneering site-specific and...
Sutro Biopharma Announces New Positive Data from the Compassionate Use of Luveltamab Tazevibulin (luvelta) in Pediatric Patients with Relapsed/Refractory CBF/GLIS Presented at ASH 2023
December 11, 2023 16:05 ET
|
Sutro Biopharma, Inc.
– Complete remission seen in 42% of patients with CBF/GLIS AML with ≥5% blasts and 75% of pediatric patients with CBF/GLIS AML with <5% blasts; treatment with luvelta was either alone or in...
Sutro Biopharma to Participate in the JMP Securities Hematology and Oncology Summit
December 04, 2023 16:05 ET
|
Sutro Biopharma, Inc.
SOUTH SAN FRANCISCO, Calif., Dec. 04, 2023 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a clinical-stage oncology company pioneering site-specific and...
Sutro Biopharma Promotes Jane Chung to President and Chief Operating Officer
November 21, 2023 16:05 ET
|
Sutro Biopharma, Inc.
SOUTH SAN FRANCISCO, Calif., Nov. 21, 2023 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a clinical-stage oncology company pioneering site-specific and...
Sutro Biopharma Reports Third Quarter 2023 Financial Results, Business Highlights and Select Anticipated Milestones
November 13, 2023 16:30 ET
|
Sutro Biopharma, Inc.
- Updated luvelta data from Compassionate Use Access demonstrating anti-leukemic activity in pediatric patients with relapsed/refractory CBF2AT3-GLIS2 AML to be presented in a poster at ASH 2023 - ...